Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

医学 卡铂 贝伐单抗 内科学 肿瘤科 彭布罗利珠单抗 人口 放化疗 培美曲塞 化疗 实体瘤疗效评价标准 癌症 外科 顺铂 临床研究阶段 免疫疗法 环境卫生
作者
Krishnansu S. Tewari,Nicoletta Colombo,Bradley J. Monk,Coraline Dubot,M. Valeria Cáceres,Kosei Hasegawa,Ronnie Shapira‐Frommer,Pamela Salman,Eduardo Yáñez,Mahmut Gümüş,Mivael Olivera Hurtado de Mendoza,Vanessa Samouëlian,Vincent Castonguay,Alexander Arkhipov,Cumhur Tekin,Kan Li,Sarper Toker,Stephen J. O’Keefe,Domenica Lorusso
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:10 (2): 185-185 被引量:55
标识
DOI:10.1001/jamaoncol.2023.5410
摘要

Importance: The KEYNOTE-826 randomized clinical trial showed statistically significant and clinically meaningful survival benefits with the addition of pembrolizumab to chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer. Treatment effects in patient subgroups of the study population are unknown. Objective: To assess efficacy outcomes in patient subgroups of KEYNOTE-826. Design, Setting, and Participants: Exploratory subgroup analyses were conducted in a global, phase 3, randomized, double-blind, placebo-controlled clinical trial. Participants included women with persistent, recurrent, or metastatic adenocarcinoma, adenosquamous carcinoma, or squamous cell carcinoma of the cervix that had not been treated with systemic chemotherapy and was not amenable to curative treatment. This subanalysis was conducted from November 20, 2018, to May 3, 2021. Interventions: Pembrolizumab, 200 mg, every 3 weeks or placebo for up to 35 cycles plus chemotherapy (paclitaxel, 175 mg/m2, plus cisplatin, 50 mg/m2, or carboplatin AUC 5 [area under the free carboplatin plasma concentration vs time curve]) with or without bevacizumab, 15 mg/kg. Main Outcomes and Measures: Overall survival (OS) and progression-free survival (PFS) by investigator assessment per Response Evaluation Criteria in Solid Tumors version 1.1 in subgroups defined by use of bevacizumab (yes or no), choice of platinum (carboplatin or cisplatin), prior chemoradiotherapy (CRT) exposure only (yes or no), and histologic type (squamous or nonsquamous) in patients with programmed cell death ligand 1-positive tumors (defined as a combined positive score [CPS] ≥1) and in the intention-to-treat population. Results: A total of 617 patients (median age, 51 years; range, 22-82 years) were enrolled in the trial. In the CPS greater than or equal to 1 population, hazard ratios (HRs) for OS favored the pembrolizumab group in all subgroups: with bevacizumab (HR, 0.62; 95% CI, 0.45-0.87) and without bevacizumab (HR, 0.67; 95% CI, 0.47-0.96), use of carboplatin (HR, 0.65; 95% CI, 0.50-0.85) and cisplatin (HR, 0.53; 95% CI, 0.27-1.04), with prior CRT only (HR, 0.56; 95% CI, 0.39-0.81) and without prior CRT only (HR, 0.72; 95% CI, 0.52-1.00), and squamous (HR, 0.60; 95% CI, 0.46-0.79) and nonsquamous (HR, 0.70; 95% CI, 0.41-1.20) histologic type. In the intention-to-treat population, HRs for OS also favored the pembrolizumab group in all subgroups: with bevacizumab (HR, 0.63; 95% CI, 0.47-0.87) and without bevacizumab (HR, 0.74; 95% CI, 0.53-1.04), use of carboplatin (HR, 0.69; 95% CI, 0.54-0.89) or cisplatin (HR, 0.59; 95% CI, 0.32-1.09), with prior CRT only (HR, 0.64; 95% CI, 0.45-0.91) and without prior CRT only (HR, 0.71; 95% CI, 0.53-0.97), and squamous (HR, 0.61; 95% CI, 0.47-0.80) and nonsquamous (HR, 0.76; 95% CI, 0.47-1.23) histologic type. Similar to OS, the addition of pembrolizumab prolonged PFS across all subgroups in the CPS greater than or equal to 1 and intention-to-treat populations. Conclusions and Relevance: The findings of this trial suggest that adding pembrolizumab to chemotherapy with or without bevacizumab improved OS across subgroups of patients with persistent, recurrent, or metastatic cervical cancer. Trial Registration: ClinicalTrials.gov Identifier: NCT03635567.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
cyx-buct完成签到,获得积分10
1秒前
yangrui完成签到,获得积分10
1秒前
2秒前
LostCityInWY完成签到,获得积分10
2秒前
水沐菁华完成签到,获得积分10
3秒前
背后的念波完成签到,获得积分10
3秒前
茶多酚发布了新的文献求助10
3秒前
茶多酚发布了新的文献求助10
3秒前
茶多酚发布了新的文献求助10
3秒前
茶多酚发布了新的文献求助10
3秒前
3秒前
情怀的应助被Menand采纳,获得10
4秒前
上官若男的应助被fortuna采纳,获得10
4秒前
5秒前
知性的派大星完成签到,获得积分10
5秒前
6秒前
Lucas的应助被云下采纳,获得10
6秒前
英姑的应助被翟刚采纳,获得10
6秒前
7秒前
7秒前
Owen的应助被涂治鸿采纳,获得10
8秒前
共享精神的应助被魔术师采纳,获得10
8秒前
强健的篮球完成签到,获得积分10
9秒前
9秒前
重要的碧空完成签到,获得积分10
9秒前
9秒前
9秒前
10秒前
11秒前
小二郎的应助被知性的派大星采纳,获得10
11秒前
zdesfsfa发布了新的文献求助10
12秒前
zuizui完成签到,获得积分20
12秒前
12秒前
YAO完成签到 ,获得积分10
12秒前
12秒前
微笑宛儿完成签到,获得积分10
12秒前
13秒前
Miss朱完成签到,获得积分10
13秒前
所所的应助被丫丫采纳,获得10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160632
求助须知:如何正确求助?哪些是违规求助? 9555512
关于积分的说明 21728801
捐赠科研通 7750444
什么是DOI,文献DOI怎么找? 3427429
关于科研通互助平台的介绍 2552456
邀请新用户注册赠送积分活动 2471817